Abcombi Biosciences was formed on June 22nd, 2015 based off of research conducted in the Chemical & Biological Engineering Department at the University at Buffalo, The State University of New York. Our corporate headquarters are located in Buffalo, New York and we also possess secondary laboratory space in Toronto, ON through the Johnson & Johnson’s incubator, JLABs.
Abcombi Biosciences is a pre-clinical vaccine and therapeutic development company dedicated to delivering “smarter” vaccine and anti-infective solutions. To accomplish this, we have developed key technologies and analytical strategies to facilitate our unique protection strategies:
- Our novel biofilm model that mimics the natural progression of disease for colonizing bacteria such Streptococcus pneumoniae and Staphylococcus aureus.
- Bioinformatics, in conjunction with our biofilm model, help to identify antigens associated with specific stages of disease progression.
- A novel vaccine formulation strategy that removes the need for complex chemistry to manufacture polysaccharide conjugate vaccines.
- A broad RNA-based therapy for treating influenza infections.
At Abcombi, we harness these potent tools to provide universally protective interventions for complex diseases such as pneumonia and influenza.